> Chemicals & Drugs > Antibiotic > Lincomycin

Lincomycin

Q: What are some common applications of Lincomycin?

Lincomycin is commonly used to treat a variety of Gram-positive bacterial infections, such as those caused by Streptococcus and Staphylococcus species. It has been studied for its effectiveness against a range of these bacteria, making it a valuable antibiotic option in clinical settings and research applications.

Q: How does Lincomycin work to kill bacteria?

Lincomycin belongs to the lincosamide class of antibiotics and works by interfering with bacterial protein synthesis. This mechanism of action disrupts the essential processes that bacteria need to survive and replicate, ultimately leading to their death or inhibition.

Q: What are some common challenges in using Lincomycin effectively?

One key challenge with Lincomycin is the potential for bacterial resistance to develop over time. Proper dosing, duration of treatment, and rotation with other antibiotics are important considerations to prevent the emergence of resistant strains. Additionally, Lincomycin can have side effects, so monitoring patients closely is crucial during administration.

Lincomycin is an antibiotic medication used to treat certain bacterial infections.
It belongs to the lincosamide class of antibiotics and works by interfering with bacterial protein synthesis.
Lincomycin has been studied for its effectvieness against a variety of Gram-positive bacteria, including Streptococcus and Staphylococcus species.
Research protocols and optimized procedures for using lincomycin in scientific experiements can be found using the advanced search and comparison tools on PubCompare.ai, an AI-driven platform for enhancing research reproducibility and accuracy.

Most cited protocols related to «Lincomycin»

Constructing Bacillus subtilis Mutant Libraries

Cited 37 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017

Agar Cells Deletion Mutation Erythromycin Escherichia coli Genes Kanamycin Lincomycin Reproduction Saccharomyces cerevisiae Sodium Chloride Strains

Generating B. subtilis Mutants via Natural Competence

Cited 20 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017

Agar Antibiotics casamino acids Cells Erythromycin ferric ammonium citrate Glucose Glycerin Kanamycin Lincomycin manganese chloride Potassium Aspartate Potassium Glutamate potassium phosphate, dibasic Sodium Citrate Dihydrate Sulfate, Magnesium Tryptophan Yeast, Dried

Cultivation and Genetic Manipulation of Escherichia coli and Clostridium Species

Cited 19 times

Escherichia coli TOP10 (Invitrogen) and E. coli CA434 [39] (link) were cultured in Luria-Bertani (LB) medium, supplemented with chloramphenicol (25 µg/ml), where appropriate. Routine cultures of C. difficile 630 Δerm[40] (link) and C. difficile R20291 were carried out in BHIS medium (brain heart infusion medium supplemented with 5 mg/ml yeast extract and 0.1% [wt/vol] L-cysteine) [41] (link). C. difficile medium was supplemented with D-cycloserine (250 µg/ml), cefoxitin (8 µg/ml), lincomycin (20 µg/ml), and/or thiamphenicol (15 µg/ml) where appropriate. A defined minimal media [18] (link) was used as uracil-free medium when performing genetic selections. A basic nutritive mannitol broth for growth assays of C. difficile strains were prepared as follows : Proteose peptone no. 2 4% [wt/vol] (BD Diagnostics, USA), sodium phosphate dibasic 0.5%[wt/vol], potassium phosphate monobasic 0.1%[wt/vol], sodium chloride, 0.2% [wt/vol], magnesium sulfate, 0.01% [wt/vol], mannitol, 0.6% [wt/vol] with final pH at +/−7.35. For solid medium, agar was added to a final concentration of 1.0% (wt/vol). Clostridium sporogenes ATCC 15579 was cultivated in TYG media [7] (link). All Clostridium cultures were incubated in an anaerobic workstation at 37°C (Don Whitley, Yorkshire, United Kingdom). Uracil was added at 5 µg/ml, and 5-Fluoroorotic acid (5-FOA) at 2 mg/ml. All reagents, unless noted, were purchased from Sigma-Aldrich.

Ng Y.K., Ehsaan M., Philip S., Collery M.M., Janoir C., Collignon A., Cartman S.T, & Minton N.P. (2013). Expanding the Repertoire of Gene Tools for Precise Manipulation of the Clostridium difficile Genome: Allelic Exchange Using pyrE Alleles. PLoS ONE, 8(2), e56051.

Full text: Click here

Publication 2013

5-fluoroorotic acid Agar Biological Assay Brain Cefoxitin Chloramphenicol Clostridium Clostridium sporogenes Cycloserine Cysteine Diagnosis Escherichia coli Genetic Selection Heart Lincomycin Mannitol potassium phosphate proteose-peptone Sodium Chloride sodium phosphate Strains Sulfate, Magnesium Thiamphenicol Uracil Yeast, Dried

Markerless Deletion Using Cre-lox Recombination

Cited 15 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017

Agar Antibiotic Resistance, Microbial Antibiotics, Antitubercular Cells Cre recombinase Deletion Mutation Erythromycin Kanamycin Lincomycin Oligonucleotide Primers Plasmids Spectinomycin Strains

Molecular Characterization of Streptococcus suis Strains

Cited 14 times

S. suis strain P1/7 was isolated from an ante-mortem blood culture from a pig dying with meningitis [9] , and is ST1 by MLST [10] (link). S. suis strain BM407 is also ST1, and was isolated from CSF from a human case of meningitis in Ho Chi Minh City, Vietnam in 2004 [3] (link). S. suis strain SC84 is ST7, which is closely related to ST1, and was isolated from a case of streptococcal toxic shock-like syndrome in Sichuan Province, China in 2005 [8] (link). Strain P1/7 is resistant to gentamycin, streptomycin, neomycin, nalidixic acid, and sulfamethoxazole, and sensitive to penicillin, ampicillin, cephalotin, erythromycin, tulathromycin, clarythromycin, lincomycin, clindamycin, pirlimicin, tetracycline, trimethoprim-sulfa, ciprofloxacin, and chloramphenicol. Strain BM407 is resistant to trimethoprim-sulfamethoxazole, tetracycline, erythromycin, azithromycin and chloramphenicol and susceptible to penicillin, ceftriaxone and vancomycin. Strain SC84 is resistant to tetracycline, and susceptible to penicillin, ampicillin, cefotaxime, ceftriaxone, cefepime, meropenem, levofloxacin, chloramphenicol, erythromycin, azithromycin, clindamycin, and vancomycin [11] (link).
Bacteria were cultured in Todd-Hewitt-broth at 37°C for 18 h and pelleted at 10,000×g. The cells were resuspended in 30 ml of lysis solution (10 mM NaCl, 20 mM Tris HCl pH 8, 1 mM EDTA, 0.5% SDS) and incubated at 50°C overnight. Three ml of 5 M sodium perchlorate was added and incubated for 1 h at ambient temperature. After phenol chloroform extraction the DNA was precipitated with ethanol, spooled into deionised water and stored at −20°C. DNA was also extracted using a genomic DNA extraction kit (G-500, Qiagen).

Holden M.T., Hauser H., Sanders M., Ngo T.H., Cherevach I., Cronin A., Goodhead I., Mungall K., Quail M.A., Price C., Rabbinowitsch E., Sharp S., Croucher N.J., Chieu T.B., Thi Hoang Mai N., Diep T.S., Chinh N.T., Kehoe M., Leigh J.A., Ward P.N., Dowson C.G., Whatmore A.M., Chanter N., Iversen P., Gottschalk M., Slater J.D., Smith H.E., Spratt B.G., Xu J., Ye C., Bentley S., Barrell B.G., Schultsz C., Maskell D.J, & Parkhill J. (2009). Rapid Evolution of Virulence and Drug Resistance in the Emerging Zoonotic Pathogen Streptococcus suis. PLoS ONE, 4(7), e6072.

Full text: Click here

Publication 2009

Ampicillin Azithromycin Bacteria Blood Culture Cefepime Cefotaxime Ceftriaxone Cells Cephalothin Chloramphenicol Chloroform Ciprofloxacin Clarithromycin Clindamycin Edetic Acid Erythromycin Ethanol Genome Gentamicin Homo sapiens Levofloxacin Lincomycin Meningitis Meropenem Nalidixic Acid Neomycin Penicillins Phenol Sodium Chloride sodium perchlorate Strains Streptococcus Streptomycin Sulfamethoxazole Tetracycline Toxic Shock Syndrome Trimethoprim-Sulfamethoxazole Combination Trimethoprimsulfa Tromethamine tulathromycin Vancomycin

Most recents protocols related to «Lincomycin»

Synthesis of Oxadiazole-Piperidine Compound

Not available on PMC !

Example 30

[Figure (not displayed)]

To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (150 mg, 518 μmol) in N,N-dimethylformamide (1.50 mL) were added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (196 mg, 518 μmol), N-ethyl-N-(propan-2-yl)propan-2-amine (201 mg, 1.56 mmol, 271 μL), and 2-(benzylamino)acetic acid (89 mg, 544 μmol). The mixture was stirred at 20° C. for 16 h and filtered, and the crude filtrate was purified directly by prep-HPLC (column: Luna C8 100×30 5 μm; mobile phase: [water (10 mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give 2-(benzylamino)-1-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanone (48 mg, 110 μmol, 21%) as a yellow solid. ¹H NMR (400 MHz, METHANOL-d4) δ=7.65 (dd, J=1.8, 8.2 Hz, 1H), 7.57 (d, J=1.8 Hz, 1H), 7.40-7.30 (m, 4H), 7.28-7.22 (m, 1H), 7.06 (d, J=8.4 Hz, 1H), 4.45 (br d, J=13.7 Hz, 1H), 3.94-3.83 (m, 7H), 3.78 (s, 2H), 3.57-3.44 (m, 2H), 3.40-3.33 (m, 1H), 3.27-3.20 (m, 1H), 3.01 (t, J=11.2 Hz, 1H), 2.17 (dd, J=2.8, 13.3 Hz, 2H), 1.93-1.73 (m, 2H); LCMS (ESI) m/z: [M+H]⁺=437.3.

US11873298B2. Compounds and uses thereof (2024-01-16). JANSSEN PHARMACEUTICA NV [BE]. Inventors: Matthew Lucas [US], Bertrand Le Bourdonnec [US], Iwona Wrona [US], Bhaumik Pandya [US], Parcharee Tivitmahaisoon [US], Kerem Ozboya [US], Benjamin Vincent [US], Daniel Tardiff [US], Jeff Piotrowski [US], Eric Solis [US], Robert Scannevin [US], Chee-Yeun Chung [US], Rebecca Aron [US], Kenneth Rhodes [US].

Full text: Click here

Patent 2024

1H NMR Acetic Acid acetonitrile Amines ammonium carbonate Dimethylformamide High-Performance Liquid Chromatographies Lincomycin Methanol Oxadiazoles

Synthesis of Pyrrolidine Derivatives

Not available on PMC !

Example 26

[Figure (not displayed)]

Synthesis of 169-A.

A mixture of tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (750 mg, 3.54 mmol), 1-methylpiperidin-4-one (800 mg, 7.08 mmol) and acetic acid (2 drops) in DCE (15 mL) was stirred at 50° C. for 2 h. Then Sodium triacetoxyborohydride (1.50 g, 7.08 mmol) was added into above mixture and stirred at 50° C. for another 2 h. After the reaction was completed according to LCMS, the solvent was diluted with water (10 mL) and then extracted by DCM (10 mL×3). The combined organics washed with brine (10 mL×3), dried over anhydrous Na₂SO₄and then concentrated in vacuo. The residue was purified by column chromatography on silica gel (DCM:MeOH=100:1˜50:1) to give 169-A (750 mg, 69%) as a yellow oil.

Synthesis of 169-B.

A solution of 169-A (400 mg, 1.29 mmol) in DCM (10 mL) was added TFA (5 mL) and stirred at room temperature for 1 h. when LCMS showed the reaction was finished. The solvent was removed in vacuo to give 169-B as a crude product and used to next step directly.

Synthesis of 169-C.

A mixture of 143-C (306 mg, 0.65 mmol) and 169-B (crude product from last step) in acetonitrile (6 mL) was stirred at 50° C. for 30 min. Then Na₂CO₃(624 mg, 6.50 mmol) was added into above mixture and stirred at 50° C. for 3 h. After the reaction was completed according to LCMS, the mixture was cooled to room temperature. The Na₂CO₃was removed by filtered. The filtrate was concentrated in vacuo. The residue was purified by column chromatography on silica gel (DCM:MeOH=100:1˜20:1) to give 169-C (230 mg, 76%) as a yellow solid.

Synthesis of 169.

A mixture of 169-C (230 mg, 0.49 mmol) and Pd/C (230 mg) in MeOH (10 mL) was stirred at room temperature for 30 min under H₂atmosphere. Pd/C was then removed by filtration through the Celite. The filtrate was concentrated and the residue was purified by Pre-TLC (DCM:MeOH=10:1) to give 169 (150 mg, 70%) as a white solid.

Compounds 152, 182, 199, 201, 202, 203, 235, 236 and 256 were synthesized in a similar manner using the appropriately substituted aldehyde or ketone variant of 169.

Compound 152.

50 mg, 36%, a light yellow solid.

Compound 182.

70 mg, 38%, a red solid.

Compound 199.

50 mg, 54%, a light yellow solid.

Compound 201.

30 mg, 42%, as a yellow solid.

Compound 202.

30 mg, 42%, a yellow solid.

Compound 203.

30 mg, 18%, a yellow solid.

Compound 235.

170 mg, 87%, a white solid.

Compound 236.

70 mg, 50%, a white solid.

Compound 256.

20 mg, 8%, a light yellow solid.

Compounds 210, 211, 215, 222, 223, 242 and 262 were synthesized in a similar manner using the appropriately substituted amine variant of 169.

Compound 210.

160 mg, 96%, a tan solid.

Compound 211.

70 mg, 40%, a white solid

Compound 215.

70 mg, 75%, a white solid.

Compound 222.

30 mg, 42%, a yellow solid.

Compound 223.

35 mg, 31%, a white solid.

Compound 242.

50 mg, 34%, a white solid.

Compound 262.

38 mg, 43%, a white solid.

US11858939B2. Hetero-halo inhibitors of histone deacetylase (2024-01-02). Alkermes, Inc. [US]. Inventors: Martin R. Jefson [US], John A. Lowe, III [US], Fabian Dey [CH], Andreas Bergmann [DE], Andreas Schoop [DE], Nathan Oliver Fuller [US].

Full text: Click here

Patent 2024

Acetic Acid acetonitrile Aldehydes Amines Anabolism Atmosphere brine Celite Chromatography compound 26 compound 235 Filtration Ketones Light Lincomycin Pyrrole Silica Gel Sodium Solvents TERT protein, human

Synthesis of Novel Compound 42 Derivatives

Not available on PMC !

Example 41

[Figure (not displayed)]
1) Synthesis of Compound 42-1

[Figure (not displayed)]

Potassium carbonate (110 mg) was added to a solution of Compound 39 (200 mg) and ethyl 2-bromoacetate (100 mg) in DMF (5 mL), and the resulting mixture heated to 80° C. and stirred for 1 h under nitrogen protection. The reaction mixture was cooled to room temperature, and filtered. The filter cake was washed with ethyl acetate (2 mL). The filtrate was concentrated to obtain Compound 42-1. LCMS (ESI) m/z: 606 (M+1).

2) Synthesis of Compound 42-2

[Figure (not displayed)]

An aqueous solution of lithium hydroxide monohydrate (1M, 0.7 mL) was added to a solution of Compound 42-1 (200 mg) in tetrahydrofuran (5 mL), and the resulting mixture was stirred at 26° C. for 1 h under nitrogen protection. The reaction mixture was acidified to pH=5-6 with an aqueous solution of dilute hydrochloric acid (1M), and extracted with ethyl acetate (20 mL×3). The combined organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain Compound 42-2. LCMS (ESI) m/z: 578 (M+1).

3) Synthesis of Compound 42

[Figure (not displayed)]

Methylamine hydrochloride (18 mg) was added to a solution of Compound 42-2 (100 mg), HATU (80 mg), and triethylamine (50 mg, 494.12 μmol) in dichloromethane (5 mL), and the resulting mixture was stirred at 26° C. for 1 h. The reaction mixture was acidified to pH=5-6 with an aqueous solution of dilute hydrochloric acid (1M), and extracted with ethyl acetate (20 mL×3). The combined organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue obtained from the concentration was purified by preparative TLC and preparative HPLC to obtain Compound 42. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.68 (s, 1H), 7.95 (d, J=8.3 Hz, 1H), 7.88 (d, J=1.5 Hz, 1H), 7.76 (dd, J=8.3, 1.8 Hz, 1H), 7.31-7.36 (m, 1H), 7.29 (dd, J=8.8, 2.0 Hz, 1H), 4.51 (s, 2H), 2.90 (d, J=5.0 Hz, 3H), 2.84 (q, J=7.7 Hz, 2H), 1.62 (s, 6H), 1.29 ppm (t, J=7.5 Hz, 3H); LCMS (ESI) m/z: 591 (M+1).

US11866433B2. Diarylthiohydantoin compound as androgen receptor antagonist (2024-01-09). CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. [CN]. Inventors: Chunli Shen [CN], Chengde Wu [CN], Shenglin Chen [CN], Shuhui Chen [CN], Xiquan Zhang [CN], Xin Tian [CN].

Full text: Click here

Patent 2024

1H NMR Anabolism brine ethyl acetate ethyl bromoacetate High-Performance Liquid Chromatographies Hydrochloric acid Lincomycin lithium hydroxide monohydrate methylamine hydrochloride Methylene Chloride Nitrogen potassium carbonate sodium sulfate tetrahydrofuran triethylamine

Synthesis of Aminoalkylpyrrolidine Derivatives

Not available on PMC !

Example 11

0.18 of 1-benzoyl-3-(5′-azido-1′-pentyl)pyrrolidine (14) was dissolved in 5 ml of tetrahydrofuran, and then 0.15 g of triphenylphosphine and 2 drops of water were added and refluxed overnight. After concentration under reduced pressure, 10 ml of dichloromethane was added, and washed sequentially with water and a saturated sodium chloride solution. The reaction solution was concentrated under reduced pressure, and separated by column chromatography (dichloromethane/methanol/aqueous ammonia=10:1:0.1 vol/vol/vol), to obtain 0.16 g of an oily product 1-benzoyl-3-(5′-amino-1′-pentyl)pyrrolidine (15). LCMS: 261[M+H].

The following compounds can be prepared according to the above method of preparing the compound 15 starting from the compound 12:

PreparationMS

numberName of CompoundStructure(m/z)

161-(2,6-dimethoxybenzoyl)- 3-(5′-amino-1′- pentyl)pyrrolidine[Figure (not displayed)]
321 (M + 1)

171-(2,6-dimethoxybenzoyl)- 3-(6′-amino-1′- hexyl)pyrrolidine[Figure (not displayed)]
335 (M + 1)

181-benzoyl-3-(6′-amino-1′- hexyl)pyrrolidine[Figure (not displayed)]
275 (M + 1)

191-furoyl-3-(5′-amino-1′- pentyl)pyrrolidine[Figure (not displayed)]
251 (M + 1)

19-11-furoyl-3-(6′-amino-1′- hexyl)pyrrolidine[Figure (not displayed)]
265 (M + 1)

201-(2-thienylformyl)-3-(5′- amino-1′-pentyl)pyrrolidine[Figure (not displayed)]
267 (M + 1)

20-11-(2-thienylformyl)-3-(6′- amino-1′-hexyl)pyrrolidine[Figure (not displayed)]
281 (M + 1)

211-(2-pyrrolylformyl)-3-(5′- amino-1′-pentyl)pyrrolidine[Figure (not displayed)]
250 (M + 1)

221-(2-pyrrolylformyl)-3-(6′- amino-1′-hexyl)pyrrolidine[Figure (not displayed)]
264 (M + 1)

231-(2-pyrrolidinylformyl)-3- (5′-amino-1′- pentyl)pyrrolidine[Figure (not displayed)]
254 (M + 1)

23-11-(2-pyrrolidinylformyl)-3- (6′-amino-1′- hexyl)pyrrolidine[Figure (not displayed)]
268 (M + 1)

241-(2-tetrahydrofurylfuryl)-3- (5′-amino-1′- pentyl)pyrrolidine[Figure (not displayed)]
255 (M + 1)

251-(2- tetrahydrothienylformyl)-3- (5′-amino-1′- pentyl)pyrrolidine[Figure (not displayed)]
271 (M + 1)

25-11-(2- tetrahydrothienylformyl)-3- (6′-amino-1′- hexyl)pyrrolidine[Figure (not displayed)]
285 (M + 1)

25-21-(3-fluoro-2-thienylformyl)- 3-(5′-amino-1′- pentyl)pyrrolidine[Figure (not displayed)]
285 (M + 1)

25-31-(3-fluoro-2- pyrrolylformyl)-3-(5′-amino- 1′-pentyl)pyrrolidine[Figure (not displayed)]
268 (M + 1)

25-41-(3-fluoro-2-furylformyl)-3- (5′-amino-1′- pentyl)pyrrolidine[Figure (not displayed)]
269 (M + 1)

261-(2-indolylformyl)-3-(5′- amino-1′-pentyl)pyrrolidine[Figure (not displayed)]
300 (M + 1)

26-11-(2-indolylformyl)-3-(6′- amino-1′-hexyl)pyrrolidine[Figure (not displayed)]
314 (M + 1)

271-(2-benzofurylformyl)-3- (5′-amino-1′- pentyl)pyrrolidine[Figure (not displayed)]
301 (M + 1)

27-11-(2-benzofurylformyl)-3- (6′-amino-1′- hexyl)pyrrolidine[Figure (not displayed)]
315 (M + 1)

27-21-(2- benzyltetrahydrofurylfuryl)- 3-(5′-amino-1′- pentyl)pyrrolidine[Figure (not displayed)]
303 (M + 1)

[Figure (not displayed)]

US11873284B2. Pyridinylcyanoguanidine derivative and use thereof (2024-01-16). None [CN], Rushi Biotech (Hangzhou) Co., Ltd [CN]. Inventors: Zheming Wang [CN], Hao Tan [CN].

Full text: Click here

Patent 2024

Ammonia Chromatography Lincomycin Methanol Methylene Chloride Oils Pressure pyrrolidine Saline Solution tetrahydrofuran triphenylphosphine

Synthesis of N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-N-methyl-benzamide

Not available on PMC !

Example 22

[Figure (not displayed)]

To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (150 mg, 518 μmol) in N,N-dimethylformamide (2 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (196 mg, 518 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (201 mg, 1.56 mmol, 271 μL) and 2-[benzoyl(methyl)amino]acetic acid (105 mg, 544 μmol). The mixture was stirred at 20° C. for 5 h, then cooled and purified directly by prep-HPLC (column: Luna C8 100×30 5 μm; mobile phase: [water (10 mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give N-[2-[4-[3-(3,4-dimethoxyphenyl) -1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-N-methyl-benzamide (133 mg, 282 μmol, 54%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ=7.59 (dd, J=1.8, 8.4 Hz, 1H), 7.49-7.32 (m, 5H), 7.27 (br d, J=6.8 Hz, 1H), 7.16-7.08 (m, 1H), 4.44-4.24 (m, 2H), 4.21-4.03 (m, 1H), 4.02-3.88 (m, 1H), 3.88-3.74 (m, 6H), 3.56 (br d, J=13.7 Hz, 1H), 3.48-3.33 (m, 1H), 3.11-2.77 (m, 5H), 2.20-1.99 (m, 2H), 1.86 (br t, J=12.6 Hz, 1H), 1.74-1.48 (m, 2H), 1.43-1.26 (m, 1H); LCMS (ESI) m/z: [M+H]⁺=465.3.

Full text: Click here

Patent 2024

1H NMR Acetic Acid acetonitrile Amines ammonium carbonate benzamide Dimethylformamide High-Performance Liquid Chromatographies Lincomycin N-methylbenzamide Oxadiazoles Sulfoxide, Dimethyl

Top products related to «Lincomycin»

Xbridge c18 by Waters Corporation

Sourced in United States, Ireland, Australia

The XBridge C18 is a high-performance liquid chromatography (HPLC) column designed for reversed-phase separation of a wide range of analytes. It features a silica-based stationary phase with a C18 alkyl bonding for effective retention and separation of both polar and non-polar compounds.

Gemini c18 by Phenomenex

Sourced in United States, Italy, Japan, Germany

The Gemini C18 is a reversed-phase liquid chromatography column designed for the separation and analysis of a wide range of organic compounds. It features a fully porous silica-based stationary phase with a C18 alkyl bonded ligand. The column is capable of operating at high pressure and temperature conditions, making it suitable for a variety of analytical applications.

Lcms 2020 by Shimadzu

Sourced in Japan, Germany, United States, Uruguay, Canada, Italy

The LCMS-2020 is a liquid chromatography-mass spectrometry (LC-MS) system developed by Shimadzu. It is designed to provide accurate and reliable analysis of a wide range of compounds. The system combines a high-performance liquid chromatograph (LC) with a triple quadrupole mass spectrometer (MS) to enable sensitive and selective detection of target analytes.

Boston prime c18 by Boston Scientific

The Boston Prime C18 is a laboratory equipment product designed for chromatographic separations. It is a high-performance reversed-phase liquid chromatography (RPLC) stationary phase used for the analysis and purification of a wide range of organic compounds.

Prep hplc by Waters Corporation

Sourced in United States

Prep-HPLC is a high-performance liquid chromatography (HPLC) system designed for preparative-scale purification. It provides efficient separation and purification of compounds from complex mixtures.

Accela 1250 uhplc by Thermo Fisher Scientific

Sourced in United States

The Accela 1250 UHPLC is a high-performance liquid chromatography system designed for the separation and analysis of complex samples. It features a maximum operating pressure of 1,250 bar and delivers a flow rate range of 0.001 to 2.0 mL/min. The Accela 1250 UHPLC is capable of performing ultra-high-performance liquid chromatography (UHPLC) applications.

Lcms it tof by Shimadzu

Sourced in Japan, United States

The LCMS-IT-TOF is a liquid chromatography-mass spectrometry (LC-MS) instrument manufactured by Shimadzu. It combines liquid chromatography with an ion trap time-of-flight (IT-TOF) mass analyzer, providing high-resolution and accurate mass measurements for the analysis of complex samples.

Lcms 8040 by Shimadzu

Sourced in Japan

The LCMS-8040 is a liquid chromatography-mass spectrometry (LC-MS) system manufactured by Shimadzu. It is a triple quadrupole mass spectrometer designed for rapid and sensitive quantitative analysis of a wide range of analytes in complex matrices.

Synergi c18 by Phenomenex

Sourced in Germany

Synergi C18 is a reversed-phase high-performance liquid chromatography (HPLC) column. It features a silica-based packing material with chemically bonded C18 alkyl chains, which provides effective separation of a wide range of nonpolar to moderately polar compounds.

Luna c18 by Phenomenex

Sourced in United States, Japan, Germany, United Kingdom, Italy, France, Australia

The Luna C18 is a high-performance liquid chromatography (HPLC) column designed for the separation and analysis of a wide range of compounds. It features a spherical silica-based stationary phase with chemically bonded C18 functional groups, providing excellent retention and selectivity for non-polar and moderately polar analytes.

What are some common applications of Lincomycin?

How does Lincomycin work to kill bacteria?

Are there different variations or types of Lincomycin?

While Lincomycin is the primary form of this antibiotic, there may be some structural variants or derivatives that have been developed for specific purposes. These could include modifications to improve solubility, stability, or targeted delivery. Researchers should review the literature to understand any unique properties or applications of different Lincomycin types.

What are some common challenges in using Lincomycin effectively?

How can PubCompare.ai help with Lincomycin research?

PubCompare.ai's advanced search and comparison tools can assist researchers in optimizing their use of Lincomycin. The platform allows you to efficiently screen the protocol literature to identify the most effective procedures related to Lincomycin. Its AI-driven analysis can also highlight key differences in protocol effectiveness, enabling you to choose the best option for reproducibility and accuracy in your research.

More about "Lincomycin"

Lincomycin is a potent antibiotic medication known for its effectiveness against a variety of Gram-positive bacterial infections.
This lincosamide class antibiotic works by disrupting bacterial protein synthesis, making it a valuable tool in the fight against pathogens like Streptococcus and Staphylococcus species.
Researchers can find a wealth of information on optimized Lincomycin protocols and procedures using the advanced search and comparison capabilities of PubCompare.ai, an AI-driven platform that enhances research reproducibility and accuracy.
This platform allows scientists to locate the best Lincomycin research protocols from the literature, preprints, and patents, ensuring they have access to the most up-to-date and effective methods.
Lincomycin has been extensively studied for its antimicrobial properties, and its use in scientific experiments is well-documented.
Researchers can leverage the insights gained from studies utilizing analytical techniques like XBridge C18, Gemini C18, LCMS-2020, Boston Prime C18, Prep-HPLC, Accela 1250 UHPLC, LCMS-IT-TOF, LCMS-8040, Synergi C18, and Luna C18 to optimize their Lincomycin research protocols and achieve reliable, reproducible results.
By harnessing the power of PubCompare.ai's AI-driven analysis and recommendations, scientists can streamline their Lincomycin research, saving time and resources while ensuring the highest level of accuracy and reproducibility.
This platform is an indispensable tool for anyone working with this important antibiotic.